Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1996 1
1997 1
1998 3
1999 1
2000 6
2001 2
2002 3
2003 2
2005 3
2007 4
2008 9
2009 8
2010 5
2011 9
2012 6
2013 5
2014 5
2015 2
2016 3
2017 5
2018 3
2019 2
2020 5
2021 5
Text availability
Article attribute
Article type
Publication date

Search Results

85 results
Results by year
Filters applied: . Clear all
Page 1
Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture.
Turk JR, Deaton AM, Yin J, Stolina M, Felx M, Boyd G, Bienvenu JG, Varela A, Guillot M, Holdsworth G, Wolfreys A, Dwyer D, Kumar SV, de Koning EM, Qu Y, Engwall M, Locher K, Ward LD, Glaus C, He YD, Boyce RW. Turk JR, et al. Among authors: stolina m. Regul Toxicol Pharmacol. 2020 Aug;115:104697. doi: 10.1016/j.yrtph.2020.104697. Epub 2020 Jun 23. Regul Toxicol Pharmacol. 2020. PMID: 32590049 Free article.
Dickkopf-1 is a master regulator of joint remodeling.
Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A, Smolen J, Hoffmann M, Scheinecker C, van der Heide D, Landewe R, Lacey D, Richards WG, Schett G. Diarra D, et al. Among authors: stolina m. Nat Med. 2007 Feb;13(2):156-63. doi: 10.1038/nm1538. Epub 2007 Jan 21. Nat Med. 2007. PMID: 17237793
Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.
Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Drüeke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG, Floege J; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators*. Moe SM, et al. Among authors: stolina m. Circulation. 2015 Jul 7;132(1):27-39. doi: 10.1161/CIRCULATIONAHA.114.013876. Epub 2015 Jun 9. Circulation. 2015. PMID: 26059012 Free article. Clinical Trial.
Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength.
Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C. Li X, et al. Among authors: stolina m. J Bone Miner Res. 2008 Jun;23(6):860-9. doi: 10.1359/jbmr.080216. J Bone Miner Res. 2008. PMID: 18269310 Free article.
Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.
Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, Chen C, Li L, Cattley RC, Van G, Scully S, Elliott R, Grisanti M, Morony S, Tan HL, Asuncion F, Li X, Ominsky MS, Stolina M, Dwyer D, Dougall WC, Hawkins N, Boyle WJ, Simonet WS, Sullivan JK. Kostenuik PJ, et al. Among authors: stolina m. J Bone Miner Res. 2009 Feb;24(2):182-95. doi: 10.1359/jbmr.081112. J Bone Miner Res. 2009. PMID: 19016581 Free article.
RANKL inhibition: from mice to men (and women).
Stolina M, Kostenuik PJ, Dougall WC, Fitzpatrick LA, Zack DJ. Stolina M, et al. Adv Exp Med Biol. 2007;602:143-50. doi: 10.1007/978-0-387-72009-8_18. Adv Exp Med Biol. 2007. PMID: 17966399 Review.
85 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page